explore -WSS

explore

author：hotspot 2025-10-02 00:18:04 - browse：416

Seng Cheng has been working in gene therapy for nearly as long as gene therapy has been a field. As a young scientist in the early 1990s, he was part of one of three teams racing to develop a gene therapy for cystic fibrosis, a high-profile effort that resulted in national headlines, prestigious publications, and zero patients cured.

So he’s seen the field’s highs and lows. Lately, there have been a lot of both, including at Pfizer, the company Cheng called home until this summer. The pharma brought three potentially powerful gene therapies for muscular dystrophy and hemophilia into late-stage trials but, in January, chose to abandon a large portfolio of early stage candidates that relied on the same technology: adeno-associated viruses, or AAVs, a group of small bugs that scientists spent two decades taming into a gene shipping system.

The move seemed emblematic. Across the industry, AAV companies have been struggling, either shelving programs or stopping work altogether, while investors shuttled money toward new technologies such as CRISPR and its various permutations. Longtime researchers feared promising drugs, particularly for ultra-rare diseases, might get lost in the shuffle.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Morphosys mixed study results for blood cancer drug

focus

WSS

FDA's Woodcock to retire early next year

Printout prescription drug information shouldn’t go digital

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Pumping milk in bathrooms at health conferences is common

Readout LOUD podcast: A CRISPR milestone, biotech mixology

focus

explore

leisure time

How to save PrEP access — and even expand it

David Sabatini, ex

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Inaction leaves children at risk from dangerous chemotherapy drug

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

How one medical school became remarkably diverse

Morphosys mixed study results for blood cancer drug

hotspot

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Ransomware attacks on hospitals: Study outlines patient impact

World's first CRISPR

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Medicare bonuses could stop drug shortages under Senate plan

Gain of function research would be limited under House proposal

focus

focus

focus

Wikipedia